{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:45:14Z","timestamp":1793126714078,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Research Project of Hunan Provincial Health Commission","award":["Grant No. W20243236"],"award-info":[{"award-number":["Grant No. W20243236"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["Grant No. 2023JJ40419, 2023"],"award-info":[{"award-number":["Grant No. 2023JJ40419, 2023"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["Grant No. 2023JJ60331, 2023"],"award-info":[{"award-number":["Grant No. 2023JJ60331, 2023"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hunan Cancer Hospital Climb Plan","award":["Grant No. ZX2021004, 2021"],"award-info":[{"award-number":["Grant No. ZX2021004, 2021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16916-3","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T22:15:31Z","timestamp":1755814531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development and validation of a nomogram to predict failure of initial radioactive iodine therapy in differentiated thyroid cancer: a retrospective cohort study"],"prefix":"10.1038","volume":"15","author":[{"given":"Yulong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"16916_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"16916_CR2","doi-asserted-by":"publisher","first-page":"738213","DOI":"10.3389\/fendo.2021.738213","volume":"12","author":"F Cheng","year":"2021","unstructured":"Cheng, F. et al. Burden of thyroid cancer from 1990 to 2019 and projections of incidence and mortality until 2039 in china: findings from global burden of disease study. Front. Endocrinol. (Lausanne). 12, 738213. https:\/\/doi.org\/10.3389\/fendo.2021.738213 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"16916_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12020-022-03274-7","volume":"80","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Incidence and mortality of thyroid cancer in 50 countries: a joinpoint regression analysis of global trends. Endocrine 80, 355\u2013365. https:\/\/doi.org\/10.1007\/s12020-022-03274-7 (2023).","journal-title":"Endocrine"},{"key":"16916_CR4","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh, J. M. & Ahn, B. C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11, 6251\u20136277. https:\/\/doi.org\/10.7150\/thno.57689 (2021).","journal-title":"Theranostics"},{"key":"16916_CR5","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1245\/s10434-011-2129-x","volume":"19","author":"HS Kazaure","year":"2012","unstructured":"Kazaure, H. S., Roman, S. A. & Sosa, J. A. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann. Surg. Oncol. 19, 1874\u20131880. https:\/\/doi.org\/10.1245\/s10434-011-2129-x (2012).","journal-title":"Ann. Surg. Oncol."},{"key":"16916_CR6","doi-asserted-by":"publisher","unstructured":"Chu, K. P. et al. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence. Thyroid 28, 902\u2013912. https:\/\/doi.org\/10.1089\/thy.2017.0136 (2018).","DOI":"10.1089\/thy.2017.0136"},{"key":"16916_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/canjclin.40.5.299","volume":"40","author":"SM Seidlin","year":"1990","unstructured":"Seidlin, S. M., Marinelli, L. D. & Oshry, E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. CA Cancer J. Clin. 40, 299\u2013317. https:\/\/doi.org\/10.3322\/canjclin.40.5.299 (1990).","journal-title":"CA Cancer J. Clin."},{"key":"16916_CR8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4103\/wjnm.WJNM_104_20","volume":"20","author":"DJ Lubin","year":"2021","unstructured":"Lubin, D. J., Tsetse, C., Khorasani, M. S., Allahyari, M. & McGrath, M. Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience. World J. Nucl. Med. 20, 253\u2013259. https:\/\/doi.org\/10.4103\/wjnm.WJNM_104_20 (2021).","journal-title":"World J. Nucl. Med."},{"key":"16916_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"RM Tuttle","year":"2019","unstructured":"Tuttle, R. M. et al. Controversies, consensus, and collaboration in the use of (131)I therapy in differentiated thyroid cancer: A joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association. Thyroid 29, 461\u2013470. https:\/\/doi.org\/10.1089\/thy.2018.0597 (2019).","journal-title":"Thyroid"},{"key":"16916_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/BF03347243","volume":"28","author":"AS Alzahrani","year":"2005","unstructured":"Alzahrani, A. S. et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J. Endocrinol. Invest. 28, 540\u2013546. https:\/\/doi.org\/10.1007\/BF03347243 (2005).","journal-title":"J. Endocrinol. Invest."},{"key":"16916_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2214\/AJR.19.22626","volume":"215","author":"A Ciarallo","year":"2020","unstructured":"Ciarallo, A. & Rivera, J. Radioactive iodine therapy in differentiated thyroid cancer: 2020 update. AJR Am. J. Roentgenol. 215, 285\u2013291. https:\/\/doi.org\/10.2214\/AJR.19.22626 (2020).","journal-title":"AJR Am. J. Roentgenol."},{"key":"16916_CR12","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1210\/jc.2019-00177","volume":"104","author":"RM Tuttle","year":"2019","unstructured":"Tuttle, R. M. & Alzahrani, A. S. Risk stratification in differentiated thyroid cancer: from detection to final Follow-Up. J. Clin. Endocrinol. Metab. 104, 4087\u20134100. https:\/\/doi.org\/10.1210\/jc.2019-00177 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"16916_CR13","doi-asserted-by":"publisher","unstructured":"Haugen, B. R. et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1-133 (2016). (2015). https:\/\/doi.org\/10.1089\/thy.2015.0020","DOI":"10.1089\/thy.2015.0020"},{"key":"16916_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12020-020-02379-1","volume":"71","author":"M Klain","year":"2021","unstructured":"Klain, M. et al. Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer. Endocrine 71, 378\u2013384. https:\/\/doi.org\/10.1007\/s12020-020-02379-1 (2021).","journal-title":"Endocrine"},{"key":"16916_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40618-015-0319-2","volume":"39","author":"ES Mendoza","year":"2016","unstructured":"Mendoza, E. S. et al. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital. J. Endocrinol. Invest. 39, 55\u201362. https:\/\/doi.org\/10.1007\/s40618-015-0319-2 (2016).","journal-title":"J. Endocrinol. Invest."},{"key":"16916_CR16","doi-asserted-by":"publisher","first-page":"872527","DOI":"10.3389\/fendo.2022.872527","volume":"13","author":"S Li","year":"2022","unstructured":"Li, S. et al. The role of thyroglobulin in preoperative and postoperative evaluation of patients with differentiated thyroid cancer. Front. Endocrinol. (Lausanne). 13, 872527. https:\/\/doi.org\/10.3389\/fendo.2022.872527 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"16916_CR17","doi-asserted-by":"publisher","unstructured":"Lu, C. et al. Prognostic factors for postoperative papillary thyroid cancer with unexplained elevated Tg: A retrospective study. Heliyon 10, e27736 (2024). https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27736","DOI":"10.1016\/j.heliyon.2024.e27736"},{"key":"16916_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2015.0294","volume":"25","author":"PW Rosario","year":"2015","unstructured":"Rosario, P. W., Mde, F., Mourao, S., Calsolari, M. R. & G. F. & Patients with papillary thyroid carcinoma at intermediate risk of recurrence according to American thyroid association criteria can be reclassified as low risk when the postoperative thyroglobulin is low. Thyroid 25, 1243\u20131248. https:\/\/doi.org\/10.1089\/thy.2015.0294 (2015).","journal-title":"Thyroid"},{"key":"16916_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.soc.2015.08.013","volume":"25","author":"C Sturgeon","year":"2016","unstructured":"Sturgeon, C., Yang, A. & Elaraj, D. Surgical management of lymph node compartments in papillary thyroid cancer. Surg. Oncol. Clin. N Am. 25, 17\u201340. https:\/\/doi.org\/10.1016\/j.soc.2015.08.013 (2016).","journal-title":"Surg. Oncol. Clin. N Am."},{"key":"16916_CR20","doi-asserted-by":"publisher","first-page":"815207","DOI":"10.3389\/fendo.2021.815207","volume":"12","author":"L Gao","year":"2021","unstructured":"Gao, L. et al. Large-Volume lateral lymph node metastasis predicts worse prognosis in papillary thyroid carcinoma patients with N1b. Front. Endocrinol. (Lausanne). 12, 815207. https:\/\/doi.org\/10.3389\/fendo.2021.815207 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"16916_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2265.2012.04336.x","volume":"77","author":"MG Mulla","year":"2012","unstructured":"Mulla, M. G., Knoefel, W. T., Gilbert, J., McGregor, A. & Schulte, K. M. Lateral cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the lateral compartment. Clin. Endocrinol. (Oxf). 77, 126\u2013131. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04336.x (2012).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"16916_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jpedsurg.2022.01.017","volume":"57","author":"DQ Ngo","year":"2022","unstructured":"Ngo, D. Q., Le, D. T., Ngo, Q. X. & Van Le, Q. Risk factors for lateral lymph node metastasis of papillary thyroid carcinoma in children. J. Pediatr. Surg. 57, 421\u2013424. https:\/\/doi.org\/10.1016\/j.jpedsurg.2022.01.017 (2022).","journal-title":"J. Pediatr. Surg."},{"key":"16916_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.21037\/atm.2020.03.80","volume":"8","author":"G Sapuppo","year":"2020","unstructured":"Sapuppo, G., Tavarelli, M. & Pellegriti, G. The new AJCC\/TNM staging system (VIII ed.) in papillary thyroid cancer: clinical and molecular impact on overall and recurrence free survival. Ann. Transl Med. 8, 838. https:\/\/doi.org\/10.21037\/atm.2020.03.80 (2020).","journal-title":"Ann. Transl Med."},{"key":"16916_CR24","doi-asserted-by":"publisher","first-page":"101013","DOI":"10.1016\/j.drup.2023.101013","volume":"72","author":"H Shen","year":"2024","unstructured":"Shen, H. et al. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance. Drug Resist. Updat. 72, 101013. https:\/\/doi.org\/10.1016\/j.drup.2023.101013 (2024).","journal-title":"Drug Resist. Updat"},{"key":"16916_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07222-1","author":"YS Lin","year":"2025","unstructured":"Lin, Y. S. et al. Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition). Eur. J. Nucl. Med. Mol. Imaging. https:\/\/doi.org\/10.1007\/s00259-025-07222-1 (2025).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"16916_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3760\/cma.j.cn321828-20201113-00412","volume":"41","author":"Z Gao","year":"2021","unstructured":"Gao, Z. & Li, S. Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition). Chin. J. Nucl. Med. Mol. Imaging. 41, 218\u2013241. https:\/\/doi.org\/10.3760\/cma.j.cn321828-20201113-00412 (2021).","journal-title":"Chin. J. Nucl. Med. Mol. Imaging"},{"key":"16916_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12902-024-01648-8","volume":"24","author":"A Keshavarzi","year":"2024","unstructured":"Keshavarzi, A. et al. Predictors of response to radioactive iodine therapy in intermediate and high risk patients with papillary thyroid carcinoma. BMC Endocr. Disord. 24, 112. https:\/\/doi.org\/10.1186\/s12902-024-01648-8 (2024).","journal-title":"BMC Endocr. Disord"},{"key":"16916_CR28","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1210\/clinem\/dgad045","volume":"108","author":"T Tian","year":"2023","unstructured":"Tian, T., Qi, Z., Huang, S., Wang, H. & Huang, R. Radioactive iodine therapy decreases the recurrence of Intermediate-Risk PTC with low thyroglobulin levels. J. Clin. Endocrinol. Metab. 108, 2033\u20132041. https:\/\/doi.org\/10.1210\/clinem\/dgad045 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"16916_CR29","doi-asserted-by":"publisher","first-page":"752176","DOI":"10.3389\/fendo.2021.752176","volume":"12","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Nomogram predicts risk and prognostic factors for bone metastasis of pancreatic cancer: A Population-Based analysis. Front. Endocrinol. (Lausanne). 12, 752176. https:\/\/doi.org\/10.3389\/fendo.2021.752176 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16916-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16916-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:02:09Z","timestamp":1755860529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16916-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16916"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16916-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}},{"value":"This study was conducted in accordance with the ethical standards formulated in the Helsinki Declaration and approved by the Ethics Committee of the Hunan Cancer Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}}],"article-number":"30819"}}